This leads to a debate about CD47-SIRPα blocking agents that whether blocking the interaction between SIRPα and CD47 alone, independent of FcR activation, is sufficient to trigger macrophage phagocytosis and tumor cell elimination (65). Here, SIRPA is linked to neoplasm.